MGMT and glioblastoma: CheckMate 143 confirmed the safety and tolerability of nivolumab in patients with newly diagnosed glioblastoma, median overall survival with nivolumab was 33.38 (16.2 to not estimable) and 16.49 (12.94-22.08) months in patients with methylated and unmethylated MGMT promoter, respectively (36).